> ## Content Index
> Fetch the complete content index at: https://www.pharmamanufacturingiq.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pharma company opens R&D centre in Hull for addiction treatment
- URL: https://www.pharmamanufacturingiq.com/pharma-company-opens-r-d-centre-in-hull-for-addiction-treatm/
- Published: 2017-08-24T10:22:01.000Z
- Updated: 2026-10-08T12:46:32.000Z
- Description: Indivior, a speciality pharmaceutical company, has opened a $30 million research and development (R&D) centre in Hull, UK, to further advance its treatment innovation into the global addiction crisis.
- Author: PharmaManufacturing IQ Staff
- Tags: Facilities & Expansion, News, Research & Development

***Indivior, a speciality pharmaceutical company, has opened a $30 million research and development (R&D) centre in Hull, UK, to further advance its treatment innovation into the global addiction crisis.***

## Hull

This new centre represents the largest capital investment in R&D from the company and is equipped with scientific technologies including a 400 MHz nuclear magnetic resonance spectrometer, and is constructed to environmental and energy-saving standards, such as the installation of a 25 KW solar panel farm to increase use of renewable energy.

Shaun Thaxter, Chief Executive Officer of Indivior, said: “This new state-of-the-art centre is an investment in our mission to pioneer life-transforming treatments for patients struggling with addiction. Indivior’s focus on the needs of patients can be traced back decades, to the days before buprenorphine was discovered — right here in Hull — and developed as a treatment for opioid addiction. Our hope is this centre will help us further our leadership in the development of novel treatment approaches that deliver on the unmet needs of patients suffering from addiction.”

“Our Hull centre will enable Indivior to deliver on the promise of science and research as critical factors in the understanding of the neurobiological underpinnings of addiction and the discovery and development of treatment options to help transform the lives of patients suffering from addiction and to advance the addiction treatment paradigm,” added Christian Heidbreder, chief scientific officer of [Indivior](http://indivior.com/?ref=pharmamanufacturingiq.com).

“The Northern Powerhouse is about economic growth and creating jobs. It’s great that this pioneering work is taking place in Hull and has the potential to deliver life-changing treatments,” commented [Northern Powerhouse](https://northernpowerhouse.gov.uk/?ref=pharmamanufacturingiq.com) Minister Jake Berry during the opening ceremony. “This £23 million investment in a state-of-the-art facility reaffirms the North East as a hub for innovation at the heart of the Northern Powerhouse.”

Emma Hardy, MP for Hull West & Hessle, asserted: “I’m delighted that Indivior has chosen to locate its world-class R&D facility in Hull. This will serve as a real boost for our community and affirms the city of Hull as a great place to do business.”

The new R&D building will be named the Chapleo Building after Dr Chris Chapleo — one of the founding fathers of [Indivior](http://indivior.com/?ref=pharmamanufacturingiq.com) and who spearheaded the scientific quest to develop buprenorphine-based treatment. Chapleo is currently a fellow of the Royal Society of Chemistry and former chairman of the Society for Drug Research.